---
title: "Cinda Securities: Jiuzhou Pharma's DMO business maintains high growth, and the layout of new molecular business is expected to create new growth points"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/252165868.md"
description: "According to the research report from Xinda Securities, Jiuzhou Pharma's DMO business continues to experience high growth, and the layout of new molecular business is expected to become a new growth point. By the first half of 2025, the company has undertaken 1,214 innovative drug active pharmaceutical ingredient CDMO projects, covering multiple therapeutic areas, with the number of late-stage clinical and commercialization projects continuously increasing, driving performance growth. In addition, the company has established a complete technical platform for new molecular businesses such as peptides, conjugates, and small nucleic acid drugs, with the relevant market size expected to reach USD 11 billion by 2030, with a compound annual growth rate of 28.4%"
datetime: "2025-08-08T06:37:40.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/252165868.md)
  - [en](https://longbridge.com/en/news/252165868.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/252165868.md)
---

# Cinda Securities: Jiuzhou Pharma's DMO business maintains high growth, and the layout of new molecular business is expected to create new growth points

Cinda Securities' research report points out that Jiuzhou Pharma's DMO business maintains high growth, and the layout of new molecular business is expected to create new growth points. As of the first half of 2025, the company's innovative drug raw material CDMO has undertaken a total of 1,214 projects, including 1,086 clinical Phase I and II projects, an increase of 60 compared to the end of 2024; 90 clinical Phase III projects, an increase of 6 compared to the end of 2024; and 38 commercial projects, an increase of 3 compared to the end of 2024. The projects undertaken by the company cover treatment areas such as anti-tumor, anti-heart failure, anti-viral, central nervous system, and cardiovascular diseases, with the number of late-stage clinical and commercial projects continuously increasing, which is expected to drive the company's performance growth. In addition, the company has comprehensively laid out new molecular businesses such as peptides, conjugates, and small nucleic acid drugs, and has established a complete technical platform. In the first half of 2025, the new molecular business introduced more than 20 new customers, with overseas orders growing rapidly, and has completed the delivery of more than ten projects. According to Frost & Sullivan statistics, the global ADC and broader conjugate drug CRDMO market size was USD 1.5 billion in 2022, and it is expected to grow to USD 11 billion by 2030, with a compound annual growth rate of 28.4% during the period from 2022 to 2030

### Related Stocks

- [603456.CN](https://longbridge.com/en/quote/603456.CN.md)

## Related News & Research

- [BoE Gov. Bailey: We have a softening picture for growth and the labour market](https://longbridge.com/en/news/287076756.md)
- [Oops! Someone Forgot To Tell Jeanine Pirro About Trump's $1.8B J6 Slush Fund](https://longbridge.com/en/news/286831031.md)
- [BoE Gov. Bailey: It is hard to put good figures on future food prices.](https://longbridge.com/en/news/287080978.md)
- [Trump is waging a silent war on legal immigration](https://longbridge.com/en/news/287081964.md)
- [15:37 ETMuse Communications Celebrates 10 Years of Award-Winning Legal Marketing and Public Relations](https://longbridge.com/en/news/286811115.md)